Skip to content

Study · Observational study · n = 44 · 2023

3 results

A retrospective study of Cerebrolysin in patients with moderate to severe traumatic brain injury: Cognitive and functional outcomes.

Soto C, Salinas P, Muñoz D, Olivares S, González J, Sáez V, Romero V

Journal of medicine and life1 Jul 2023Cited by 2 (Europe PMC)

PMID37900065 (opens in a new tab)PMCIDPMC10600656 (opens in a new tab)DOI10.25122/jml-2023-0125 (opens in a new tab)PepBankPUB-37900065
Download PDFPubMedAsk about this study
Jump to 3 results

Summary

In this retrospective study, we aimed to evaluate the effects of the neurotrophic compound Cerebrolysin on executive, cognitive, and functional performance in patients with traumatic brain injury (TBI) with a highly severe disability level. A total of 44 patients were included in the study, with 33 patients in the control group and 11 patients in the interventional group who received intravenous infusions of 30 mL Cerebrolysin. Both groups received standard rehabilitation therapy following the rehabilitation protocol for patients with TBI at Hospital Clínico Mutual de Seguridad. Functional and cognitive scales were evaluated at baseline, at four months, and at the endpoint of the intervention therapy at seven months (on average). The results revealed a significant improvement in the Cerebrolysin-treated group compared to the control group. Specifically, patients who received Cerebrolysin showed a moderate residual disability and a significant reduction in the need for care. Concerning the promising results and considering the limitations of the retrospective study design, we suggest that randomized controlled studies be initiated to corroborate the positive findings for Cerebrolysin in patients with moderate to severe brain trauma.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In patients with traumatic brain injury, Cerebrolysin treatment was linked to improved overall performance compared with standard rehabilitation alone.

    In plain wordsIn patients with brain injury, Cerebrolysin was linked to better overall performance compared with rehabilitation alone.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseOverall functional and cognitive performance
    Study

    n = 44

    Comparator
    Standard rehabilitation without Cerebrolysin
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    30 mL · intravenousAs given in this study (human).

    Source sentences

    Summary
    The results revealed a significant improvement in the Cerebrolysin-treated group compared to the control group.
    2 context sentences
    Summary · context
    A total of 44 patients were included in the study, with 33 patients in the control group and 11 patients in the interventional group who received intravenous infusions of 30 mL Cerebrolysin.
    Summary · context
    Both groups received standard rehabilitation therapy following the rehabilitation protocol for patients with TBI at Hospital Clínico Mutual de Seguridad.
  2. 02HumanObservational studyEfficacy outcome

    In patients with traumatic brain injury, Cerebrolysin recipients had moderate residual disability.

    In plain wordsIn patients with brain injury, those who received Cerebrolysin had moderate remaining disability.

    Peptide
    Cerebrolysin
    Outcome
    Not applicableResidual disability
    Study

    n = 11

    Outcome group
    Exercise and physical function · Nervous system and cognition
    Studied dose
    30 mL · intravenousAs given in this study (human).

    Source sentences

    Summary
    Specifically, patients who received Cerebrolysin showed a moderate residual disability and a significant reduction in the need for care.
    2 context sentences
    Summary · context
    A total of 44 patients were included in the study, with 33 patients in the control group and 11 patients in the interventional group who received intravenous infusions of 30 mL Cerebrolysin.
    Summary · context
    Both groups received standard rehabilitation therapy following the rehabilitation protocol for patients with TBI at Hospital Clínico Mutual de Seguridad.
  3. 03HumanObservational studyEfficacy outcome

    In patients with traumatic brain injury, Cerebrolysin recipients showed a significant reduction in the need for care.

    In plain wordsIn patients with brain injury, those who received Cerebrolysin showed a significant reduction in the need for care.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseNeed for care
    Study

    n = 11

    Outcome group
    Exercise and physical function · Nervous system and cognition
    Studied dose
    30 mL · intravenousAs given in this study (human).

    Source sentences

    Summary
    Specifically, patients who received Cerebrolysin showed a moderate residual disability and a significant reduction in the need for care.
    3 context sentences
    Summary · context
    The results revealed a significant improvement in the Cerebrolysin-treated group compared to the control group.
    Summary · context
    A total of 44 patients were included in the study, with 33 patients in the control group and 11 patients in the interventional group who received intravenous infusions of 30 mL Cerebrolysin.
    Summary · context
    Both groups received standard rehabilitation therapy following the rehabilitation protocol for patients with TBI at Hospital Clínico Mutual de Seguridad.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.